Autolus Therapeutics (NASDAQ:AUTL) Raised to "Hold" at Wall Street Zen

Key Points

• Autolus Therapeutics has been upgraded to a "hold" rating by Wall Street Zen, shifting from a previous "sell" rating.
• Wells Fargo lowered its price target for Autolus Therapeutics from $6.00 to $5.00, while Needham & Company maintained a "buy" rating with a target of $10.00.
• The company reported earnings of ($0.18) per share for the last quarter, outperforming the consensus estimate of ($0.24), with revenues reaching $13.50 million.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

A number of other analysts have also recently commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, July 21st. Wells Fargo & Company lowered their price target on Autolus Therapeutics from $6.00 to $5.00 and set an "overweight" rating for the company in a research report on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus price target of $9.12.

Autolus Therapeutics Stock Down 3.4%

Shares of Autolus Therapeutics stock traded down $0.06 during trading on Friday, reaching $1.73. The company's stock had a trading volume of 2,410,336 shares, compared to its average volume of 2,752,232. The company has a market cap of $460.42 million, a price-to-earnings ratio of -2.06 and a beta of 1.90. Autolus Therapeutics has a 1-year low of $1.1050 and a 1-year high of $5.00. The company has a 50-day simple moving average of $2.29 and a two-hundred day simple moving average of $1.89.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.24) by $0.06. The firm had revenue of $13.50 million for the quarter, compared to analyst estimates of $12.92 million. As a group, analysts anticipate that Autolus Therapeutics will post -0.94 earnings per share for the current year.

Hedge Funds Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. Jane Street Group LLC purchased a new position in shares of Autolus Therapeutics in the 4th quarter valued at about $26,000. Barclays PLC increased its stake in shares of Autolus Therapeutics by 1,094.3% in the 4th quarter. Barclays PLC now owns 11,859 shares of the company's stock valued at $28,000 after purchasing an additional 10,866 shares in the last quarter. Marex Group plc purchased a new position in shares of Autolus Therapeutics in the 2nd quarter valued at about $28,000. R Squared Ltd purchased a new position in shares of Autolus Therapeutics in the 2nd quarter valued at about $50,000. Finally, Invesco Ltd. increased its stake in shares of Autolus Therapeutics by 53.3% in the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock valued at $51,000 after purchasing an additional 11,381 shares in the last quarter. Hedge funds and other institutional investors own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.